Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | AKT2 | P31751 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653909 | 0.80 | HTT (0.57) | HTTMAPK1TP53LMNAAKT2 | |
| SCHEMBL562493 | 0.80 | HTT (0.57) | HTTMAPK1TP53LMNAAKT2 | |
| SCHEMBL3780112 | 0.77 | HRH4 (0.51) | LMNAMAP3K5PDPK1HRH4TSHR | |
| SCHEMBL3799224 | 0.77 | XDH (0.44) | XDH | |
| SCHEMBL3768067 | 0.74 | ALDH1A1 (0.41) | HTTMAPK1TP53LMNAALOX15 | |
| SCHEMBL17364285 | 0.74 | CA12 (0.61) | HTTMAPK1TP53LMNAAKT2 | |
| SCHEMBL13140354 | 0.73 | NOTUM (0.47) | HTTMAPK1TP53LMNAALOX15 | |
| SCHEMBL3776995 | 0.72 | HTT (0.53) | HTTMAPK1TP53LMNAAKT2 | |
| SCHEMBL17371005 | 0.72 | CA12 (0.52) | HTTMAPK1TP53LMNAAKT2 | |
| SCHEMBL6762724 | 0.71 | HTT (0.51) | HTTMAPK1TP53LMNAAKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855285-B2 | Methods for selective N-9 glycosylation of purines | BRIGHAM YOUNG UNIVERSITY (US) | 2010-12-21 | — | — | US | claimed |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | BRIGHAM YOUNG UNIVERSITY (US) | 2008-08-28 | — | — | US | claimed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| CN-101257797-B | Methods for selective N-9 glycosylation of purines | UNIV BRIGHAM YOUNG | 2013-06-12 | — | — | CN | disclosed |
| US-7855285-B2 | Methods for selective N-9 glycosylation of purines | BRIGHAM YOUNG UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| CN-101257797-A | Methods for selective N-9 glycosylation of purines | UNIV BRIGHAM YOUNG (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | BRIGHAM YOUNG UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | HTT 4701/4885MAPK1 3365/4885TP53 3695/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | HTT 4701/4885MAPK1 3365/4885TP53 3695/4885 |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | PNP, SLC29A2, SLC28A2 | HTT 4119/4885MAPK1 2282/4885TP53 3966/4885 |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | HTT 3947/4885MAPK1 2645/4885TP53 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.